Index

Note: page numbers in italics refer to figures and tables.

abacavir (ABC) 342–343, 809
adverse effects 343
antiviral effects 342
drug interactions 368
NRTI combination 336–337
pharmacokinetics 342–343
resistance 342
abdominal pain 195, 615–616
differential diagnosis 195–197
evaluation 197–198
radiology 197
therapy 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HSV prophylaxis 168
resistance 261, 732
varicella zoster virus 735
adolescents 219–225
acute infection 226
anaal warts/dysplasia 227
antiretroviral therapy 226
alternative regimen 427–428
changes 430, 432
combination 121
effects 90
guidelines for initiation 416, 416–417, 418, 423, 425
initial regimen 422–429
care of infected 226–262
care programs 262
confirmation of infection 226
counseling 222–223
preventive 223
delayed puberty 228, 275
development 227, 228–251
diagnostic assays 228
disclosure 227–228
epidemiology 219–227
adipocytes 385
adiponectin (Acrp30) 385
adiposity, visceral in lipodystrophy syndrome 297–298
adherence AIDS 213
antiretroviral therapy guidelines for initiation 417
appointment keeping 212
assessment 208–212
modalities 209
behavioral change 207
chronic illness 208–214
combination therapy 356
drug level monitoring 212
electronic monitoring 211–212
improving 212–214, 215
lack 336
nursing intervention 213–214
patient routine 213
pharmacy refill records 211
pill counts 210–211
provider assessment 210
rewards 213
self-reporting 208–210
Stages of Change Model 214
token economy 213
abdominal pain 195
perirectal 669
splenic 197, 198
absence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abscess hepatic 198
perirectal 669
splenic 197, 198
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
abstinence, sexual 238
acid–base disorders 619
acute phase reactants 6
acyclovir drug interactions 368
HIV prophylaxis 168
resistance 261, 732
treatment 732
varicella zoster virus 735
adolescents (cont.)
gynaecologic care 227
gynecology
non-infectious 228–244
sexually transmitted infections 244
health education 262
history taking 226
human papilloma virus 227
immunization schedule 139
infection
high risk 224–225
incidence 80
menstrual disorders 229–238
mental health 262
mental health evaluation/monitoring
neurobehavioral assessment 316–317
outreach to “at risk” youth 282
peer educators 262
postexposure prophylaxis 460
pregnancy 243
prevention 223–226
psychosocial issues 772
referral 223
reproductive health
non-infectious 228–244
sexually transmitted infections 244
seroepidemiology 262–266
sexual history 227
sexual transmission 227, 244
SHADSSS assessment 224
testing for HIV 222–223
transmission 219–221
adolescents
adolescent hyperandrogenic–insulin resistant
acanthosis nigricans (HAIRAN) 232
syndrome 232
adrenal hyperandrogenic–insulin resistant
acanthosis nigricans (HAIRAN) 232
syndrome 232
adrenal insufficiency 296–297
adrenocortical insufficiency 632–634
diagnosis 633
mechanisms 633
treatment 633–634
adults
antiretroviral therapy
changes 430
guidelines for initiation 416, 416–417, 425
initial therapy 429
Africa, HIV-1 natural history 55
AIDS Clinical Trials Group (ACTG) protocol
109
AIDS Community Care Alternatives waiver
776
AIDS Drug Distribution Program (ADIDP)
775–776
AIDS reporting 78–87
AIDS-defining conditions
frequency 89, 88–90
invasive cervical cancer 257
PCP 58
airway disease, reactive 188, 573–577
amenorrhea 230–231
diagnosis and surveillance 230
management 231
pregnancy 230
primary 230
secondary 230
workup 230
amphotericin B 607, 711
drug interactions 368
AmpliClov HIV-1 detection kits 104
amprenavir (APV) 348, 811
adverse effects 348
antiviral effects 348
drug interactions 368
pharmacokinetics 348
resistance 348
analytical and clinical 227
anal warts/dysplasia, adolescents 227
anaemia 588–589
causes 589
diagnosis 590
iron levels 279
laboratory evaluation 590–591
treatment 591
angiotensin antagonist therapy 626–627
anorexia 604–611
medications 290–291
anthropometric measurements 278
fat redistribution 387
guidelines 283
antibiotics
bacterial gastroenteritis 56
bacterial infections 653–661
diabetes 44
otitis media 567, 547–550
respiratory disease 461
bacterial infections 661
Campylobacter 662
Escherichia coli 668
Haemophilus influenzae 664
Pseudomonas 662
Staphylococcus aureus 55
Staphylococcus epidermidis 661
Streptococcus pneumoniae 186, 681–682
tuberculosis 680–681
Index
© Cambridge University Press www.cambridge.org
respiratory distress 191
sinusitis treatment 547, 547–550
antibodies 6
detection 99–101
production defects 39
anticoagulation 597
anti-D, intravenous 595
antifungal agents 695
cryptococcosis 714
drug interactions 368
systemic 697
antigen presentation 9
antigens-presenting cells 9, 12
function defects 37
antigen-specific immunity 7–13
antineoplastic therapy 646
antiretroviral therapy 34, 646
absorption 360
administration during breastfeeding 115
adolescents 99, 226
adults 49–50
adverse effects 461
agents 336
cardiovascular interactions 562
cervical lesion recurrence 259
changes 429–433
adolescents 430, 356
adults 439
clinical considerations 432–433
clinical disease progression 434–435
due to toxicity/intolerance 433
immunologic considerations 432
immunologic disease progression 434–435
infants 431
postexposure prophylaxis 461–462
reversal of fat redistribution syndrome 388–389
therapeutic drug monitoring results 446
virologic considerations 436–432
virologic disease progression 434–435
CNS disease 512–513, 514
combination 109–121, 355
adherence 356
regimen 422
dosages 336
drug interactions 365, 368
pharmacodynamic 366–379
pharmacokinetic 360–366
drugs 362
distribution 362
excretion 366
holidays 435
metabolism induction 360–366
dyslipidemia 385–386
formulary 336, 807–820
growth relationship 276
guidelines 415
guidelines for initiation 121–125, 416–422
adolescents 416, 416–417, 418, 423, 425
adult 416, 416–417, 425
European Pediatric ART Guidelines 419, 420
infants 418, 417–419, 423
WHO for Resource-Limited Settings 419, 421
HIV biology 335–336
HIV encephalopathy risk 310
insulin resistance 385–386
metabolic complications 382
metabolism of drugs 362–366
MTCT prevention 109
Mycobacterium avium complex treatment 691–692
nausea 612
neuropsychiatric function 323
ocular toxicity 531–532
offered to mothers and infants 87
pancreatitis 616
pediatric 155
perinatal transmission prophylaxis 109
plasma concentrations 439
pregnant women 121
postexposure prophylaxis 110
maternal presentation time 122
perinatal transmission 135–162, 168
postexposure 460–462
received by mothers and infants 87
regimen 109
adolescents 426–429
alternative 427–428
changes 429–433
choosing new 433–435
failure 429
initial therapy 422–429
insufficient data 428–429
not recommended for initial therapy 428
resistance 397–411
assays 406–407, 409
development 125–126, 336
testing in clinical practice 410–411
safety in MTCT prevention 125
salvage 336
side effects 366–379
suboptimal 336
therapeutic drug monitoring 439–446
therapeutic range 440
therapeutic window 439
antiretroviral therapy (cont.)
thrombocytopenia 595
toxicity 433
adjunctive therapies 433
non-nucleoside reverse transcriptase inhibitors (NNRTIs); nucleoside reverse transcriptase inhibitors (NRTIs); nucleotide reverse transcriptase inhibitors; protease inhibitors
aphthous ulcers, recurrent 604
appendicitis 195–196, 197, 198
abdominal pain 616
appointment keeping, adherence 212
arm measurements
mid-arm circumference (MAC) 278
reference 280
arrhythmias 564
arthritis, septic 669–670
arthropod-induced disease 493–498
Aspergillus (aspergillosis) 696, 714–715
CNS infection 504
pulmonary 573
treatment 708
asthma 573–577
dosages for medications 580
management 577, 578
antibiotics 541, 542
atazanavir (ATZ) 353–354, 812
adoptive effects 354
antiretroviral effects 354
pharmacokinetics 354
resistance 354
atherosclerosis, premature 559, 564
athletic activities 765
atorvastatin 298–299
azithromycin 689, 690
azoles 697, 710
drug interactions 368, 706
B-cell lymphoproliferative disorder, polymorphic 645
B-cells 12–13
function defects 38–39
humoral immune response 15–16, 17
bacille Calmette-Guérin (BCG) vaccine 483–482
bacteremia 663–665
catheter-associated 663–664, 665
Mycobacterium avium complex 687
bacterial infections
bacteremia 663–665
central venous catheters 669
clinical syndromes 654, 663–671
CNS 594
common 661–663
congenital syphilis 670–671
meningitis 186, 667–668
orbit 529–530
osteomyelitis 670
pulmonary 572
recurrent invasive 571
salivary gland 538–539
septic arthritis 669–670
serious 653–671
sinusitis 545–546
skin 493
soft tissue 668–669
treatment 663–671
urinary tract 668
see also named infections and organisms;
pneumonia; resistance
bartonellosis prophylaxis 167
basal ganglia calcifications 569
behavioral functioning 316
behavioral observations 322
benefit entitlement for child 797–798
see also Supplemental Security
Income
benzodiazepines, seizures control 291
bereavement 781–794
books 782
emotional development 782
parents 788–791
reading materials 792
resources 786, 787
social development 782
bile duct, common, obstruction 815
bioelectrical impedance analysis 285
birth history 321
bites
human 452–453, 761–762
wounds 459–469
see also insect bite reaction
blastocondesis treatment 708
blood
transmission of infection 80, 452
in urine 622, 623–622
see also coagulation abnormalities
blood cultures
bacteremia 663–664
*Mycobacterium avium* complex 687
blood products, transmission of infection 80
blood transfusion, infected donor 452
blood–brain barrier, virus trafficking across 512
body composition
assessment 285–286
nutritional status 276
body fluids
transmission 760–761
body mass index (BMI) 279, 285
reference values 282
bone mineral density 299
bowel obstruction, abdominal pain 616
brain
calcifications 508–509
CT scan 508–509
HIV infection 309
brush border enzymes 603
buffalo hump 384
Burkitt’s lymphoma 530, 638
cachexia 290
calcifications, brain 588–589
calcium
metabolism 634–635
treatment 635
increased 603
calories, boosting 293–294
*Campylobacter jejuni* bacteremia 665
*Candida* (candidiasis) 696
cervicitis 250–251
CNS infection 594
cutaneous 695–707
diaper dermatitis 695–707
disseminated 711–714
epiglottitis 711
esophageal 711, 733
esophageal plaques 712
esophagitis 196, 198, 611
laryngeal 711
mucocutaneous 476–477
oral 479, 537, 538
infants 117, 120
oral mucosa 535–537
oesophagitis 710–711
overgrowth in stomach 611
prophylaxis 167–168
treatment 798
vulvovaginal 245, 248–249, 711
treatment 249
capreomycin drug interactions 368
carbohydrate intolerance 295
cardiac arrhythmias 553–556
cardiac catheterization 559
cardiac disease, respiratory
signs/symptoms 554
cardiac malignancy 556
cardiac problems 554–565
cardiomyopathy 555, 563
cardiovascular disease 554
diagnosis 557, 558, 560
management 560, 563
patient evaluation 557–562
referral of patients 565
risk factors 554–555
serum laboratory tests 559
types 555
child care
adolescents 262
general medical care 148–150
mental access 778
neonatal care 227
HIV-exposed infant 236, 134–155
infected adolescents 226–262
managed 774–777
psychosocial issues 772–773
social service agencies 772–779
see also permanent custody planning
caregivers
adherence 206–207
food availability 283
multiple 277
self-report 208–210
caries 540, 548–541
bacteremia 663–664
bacterial infections 669
fever 185
cerebrospinal fluid (CSF) analysis in seizures 201
studies 510–511
cerebrovascular disease 504
cerebral aneurysms 199
cerebral dysplasia 257
invasive 257
treatment 257
cervix, strawberry 251
cesarean delivery
clinical trials 116
HSV prophylaxis 168
before labor and ruptured membranes 128–129
MTCT prevention 87
risk reduction 135–162
chemokines 11
chest X-ray
fever 186
FEP 189
respiratory distress 188
chickenpox see varicella
child welfare agencies 777–778
children
death of family member 782
non-infected 773, 785
over 12 months, guidelines for initiation of therapy 419
see also infected child; permanent custody planning
Chlamydia trachomatis
cervicitis 250–251
pelvic inflammatory disease 251–254
cholangiopathy, ascending 724
cholecytitis 198
chiorionitis 116
primary 505–512
epidemiology 506
secondary disorders 503–504
treatment 512–515
symptomatic 515
varicella zoster virus 734
central venous catheters
bacteremia 663–664
bacterial infections 669
fever 185
cerebrospinal fluid (CSF) analysis in seizures 201
studies 510–511
cerebrovascular disease 504
cervical cancer 638, 644–645
invasive 257
treatment 644–645
cervical dysplasia 255–257, 638
cervical intra-epithelial neoplasia (CIN) 253, 644–645
cervical lesion management 258–259
cervicis 250–251
diagnosis 251
mucopurulent 250–251, 252
prevention 251
treatment 251
cervix, strawberry 251
cesarean delivery
clinical trials 116
HSV prophylaxis 168
before labor and ruptured membranes 128–129
MTCT prevention 87
risk reduction 135–162
chemokines 11
chest X-ray
fever 186
FEP 189
respiratory distress 188
chickenpox see varicella
child welfare agencies 777–778
children
death of family member 782
non-infected 773, 785
over 12 months, guidelines for initiation of therapy 419
see also infected child; permanent custody planning
Chlamydia trachomatis
cervicitis 250–251
pelvic inflammatory disease 251–254
cholangiopathy, ascending 724
cholecytitis 198
chiorionitis 116
cidofovir 815
cytomegalovirus 726–728
drug interactions 368
circle of Willis 504
vasculopathy 504
clarithromycin 689, 690, 815
drug interactions 368, 691–692
clindamycin 815
drug interactions 368
clindamycin/primaquine, PCP treatment 748
clinical trials
counsel for participation 801
units 821–825
clofazimine, drug interactions 368
clofazimine 504
clofazimine/sulfonamides 504
clofazimine/adverse effects 504
clotrimazole 710–711
coagulation abnormalities 596, 598–598
cognitive function 312, 508
colpitis macularis 251
colonoscopy, human papilloma virus 708
complement 6, 13
treatment 708
corneal Q 300
cognitive abilities, chronic illness 207
cognitive function 312, 308
colitis 505–508
corticosteroids 581
inhaled 581
cough, chronic 572–573
counseling 86–87
adolescents 222–223
pregnancy 244
preventive 223
contraception 238
resource poor settings 119
safer sex 225
sexuality 225–226
sexually transmitted infection prevention 261
US 118–119
voluntary 118–118
cryptococcosis 696, 714
fever 183
Cryptosporidium 192
Cryptosporidium (cryptosporidiosis) 192
Chronic atrophy 508–509
corticosteroids 508–509
cranial nerve abnormalities 505
CYP3A activity 362
CYP450 activity 362–365
cyclophosphamide 291
cytokines 10
inflammatory 297
production 15
Cytomegalovirus (CMV) 721–729
antigenemia 725
cough, chronic 572–573
counselling 86–87
adolescents 222–223
pregnancy 244
preventive 223
contraception 238
resource poor settings 119
safer sex 225
sexuality 225–226
sexually transmitted infection prevention 261
US 118–119
voluntary 118–119
cryptococcosis 696, 714
fever 183
Cryptosporidium 613
enteric 194
pancreatic duct obstruction 616
prophylaxis 146–167
Cryptosporidium parvum 613
custody planning 796–799
Cutaneous diseases 473–501
bedside procedures 478
evaluation 474, 474, 477
non-infectious 486–501
primary lesions 475
secondary lesions 475
see also Skin infections
Cyclospora cayetanensis 815
CYP3A activity 362
CYP450 activity 362–365
Cytomegalovirus (CMV) 721–729
antigenemia 725
Central nervous system 724, 725
cryptococcosis 696, 714
fever 183
Cryptosporidium 613
CNS infection 505–506
co-infection 165–166, 555
colloid 723, 725
congenital infection 722
culture 724–725
diagnosis 724–725
diarrhea 195
cytomegalovirus (CMV) (cont.)
edemiology 721–722
esophagitis 611, 725
gastrointestinal bleeding 182, 723
gastrointestinal disease 723–724, 725
HAART 729
hepatitis 724
HIV progression 723
rate 722
jaundice 615
local therapy 728–729
maintenance therapy 728, 729
odynophagia 610
pancreatic duct obstruction 616
PCP co-infection 189
perinatal infection 722
pneumonia 724, 725
prophylaxis 165–166
pulmonary disease 724
respiratory distress 189
retinitis 523, 525, 523–525, 723
immune recovery uveitis 525
treatment 524
seropositivity 722
transmission 165–166
treatment 727, 725–729
cytotoxic T cells see CD8+ T cells
dapsone 816
drug interactions 368
dapsone/trimethoprim 748
day care centers 768
dehydration 193
delavirdine (DLV) 345, 346, 362, 809
adverse effects 346
antiviral effects 346
drug interactions 368
pharmacokinetics 346
resistance 346
delivery mode
clinical trials 116
see also cesarean delivery
dendritic cells 7, 14
dental care 604–610
dental decay 540, 548–541
dental development 540
dermatophytosis 477–478, 482, 710
developing countries see resource-poor settings
development assessment 149
change 317–319
history 321
delay 277
grief impact 783
see also neurodevelopment
diabetes mellitus
management 233
megestrol acetate 610
protease inhibitors 632
treatment 634
diagnosis 99–104
adolescents 226
age at 178–192
confirmation in adolescents 226
disclosure 782
DNA detection methods 101
heat denaturation of plasma methods 102
HIV infection in infants/children 102–104
HIV-1 culture 102
infants born to HIV-infected women 135–169
infected child 154
non-subtype B HIV-1 104
perinatal 87
RNA detection methods 101
viral p24 antigen detection 101–102
virologic assays 44–45
diagnostic assays 99–103, 104
clinical interpretation 100–101
rapid methods 100
diagnostic tests in infected child 152
diarrhea 193
daycare 214, 679, 681
differential diagnosis 192
evaluation 194, 192–194, 613
fluid therapy 195
increased nutrient losses 294
postexposure prophylaxis 461
resistance 338
stool 214, 679, 681
diabetic ketoacidosis 339–340
disability 208–209
definition 208
discharge planning 776–777
disclosure 782
infected status 763–764, 765
adolescents 227–228
Index

discrimination 778
disseminated intravascular coagulation (DIC) 593
dronabinol 291
drug use/abuse
  injection
  needle sharing 460
  transmission 83
  prenatal care 85
drugs, pharmaceutical
  conjugation reactions 365–366
  drug holidays 435
  eruptions 499
  fixed 501
  skin 498–501
  excretion 366
  food interactions 361
  level monitoring adherence 212
  metabolism induction 365–366
  overlapping toxicity 367
  see also adherence; medication; therapeutic drug monitoring
dual-energy X-ray absorptiometry (DEXA) 285, 286
  fat redistribution 387
dyslipidemia
  antiretroviral therapy 385–386
  diagnosis 387–388
  evaluation 298
  management 298
  NRTIs 386
  PI therapy 385
dysmenorrhea 235–237
  diagnosis 236
  treatment 236
dysphagia 604–611
eating, exacerbation of symptoms 291
  echocardiography 557–559
  ectocervicitis 250, 251
  education
  family 170–171
  history 321
  infected children 170, 764–765
  efavirenz (EFV) 345, 346–347, 385, 810
  adverse effects 347
  antiviral effects 347
  drug interactions 368
  pharmacokinetics 347
  resistance 347
  electrocardiography 559
  electrolyte disorders 618–619
  electronic monitoring of adherence 211–212
  emancipation 801
  emergency department
  fever presentation 182–187
  gastrointestinal emergencies 192–198
  HIV testing 180–182
  life-threatening complications 182
  potential 181
  presentation 181–182
  neurologic emergencies 198–202
  neurologic problem presentation 182
  postexposure prophylaxis 181
  presentation 177–183
  respiratory distress 187–192
  emesis 197
  with diarrhea 192
  emotional development 782
  encephalitis
  HIV 511
  HSV 731
  MRI 732
  varicella zoster virus 734
  encephalopathy, cytomegalovirus-related 724
  encephalopathy, HIV 199, 309
  autonomic neuropathy 554, 555–556
  clinical manifestations 567
  pattern 311
  progressive 506–507
  plateau type 311, 507
  subacute 311, 506
  risk 310
  static 311, 507–508
  endocarditis 556, 564
  endocervicitis 250–251, 252
  edentulous disorder 638–635
  amenorrhea 230
  dysregulation in malnutrition 296
  energy
  recommended daily intake 287
  requirement estimation 296
  total expenditure 296
  enfuvirtide (ENF) 336, 354–355, 362, 812
adverse effects 355
  antiviral effects 354–355
  pharmacokinetics 355
  resistance 354–355
  enteral feeding 283, 285
  enteric infections 603
  prevention 277
  Enterococcus bacteremia, catheter-associated 605
  enteropathogenic pathogens, therapy 614
environmental factors, neurobehavioral assessment 321
enzyme immunoassays 44
enzyme-linked immunosorbent assay (ELISA) 99–100
HIV-1 diagnosis 104
p24 antigen detection 101–102
epidemiology
adolescents 219–227
children in US 82, 78–90
global 90–92
incidence of infection 79
US 81, 83–84
mode of acquisition 80–85
non-perinatal 80
morality 87–90
perinatal prevention cascade 85–87
see also mother-to-child transmission, transmission
Epidermophyton floccosum 710
epithelial barriers 13
Epstein–Barr virus (EBV) 638, 736
coinfection 555
lymphoproliferative syndromes 736
oral lesions 537–538
erethema multiforme 501
erythromycin, drug interactions 368
erthropoiesis suppression 588–590
erthropoietin 591
Escherichia coli
pneumonia 665
resistance 678
ethambutol 678, 679, 689, 690, 816
drug interactions 368
elastic factors
incidence of infection 78–92
infected women 83
prenatal care 85
European Pediatric ART Guidelines 419, 420
exercise stress testing 559
exposure to HIV
breast milk 460
care of infants 134–135
contact type 452
immunizations 138–171
infant care 136, 134–155
management 769
maternals containing HIV 451
non-occupational 454–456
opportunist infection prophylaxis 148
patient management 458
percutaneous 452, 459–460
reporting
risk categories 456
sex 456–459
significant 463
source material
infection status 457
type 458–451, 455
virus concentration 451
virus viability 452
volume 451
transmission risk after 450–453
types 453, 456
see also postexposure prophylaxis
eyes, trichomegaly 500
eyelids, molluscum contagiosum 522
failure to thrive (FTT) 273–274
infected child 275–277
famciclovir 816
HSV resistance 261
HSV treatment 732
family
assessment 170–171
challenges 778
contact 184–185
education 170–171
empowerment 778
factors in neurobehavioral assessment 321
interaction with multiple agencies 777
management decision involvement 170
needs assessment 773–774
poverty 773–774
stress 774
support 170–171
symptom recognition 184–185
treatment decision involvement 170
fat, body
distribution 285–286, 385
redistribution 298, 381
failure to thrive 277
fat, malabsorption of dietary 295
Index
feeding difficulties in neurologic dysfunction 293
enteral 293, 295
parenteral 296
 fibre 294
fever causes 183
control 185
emergency department presentation 182–187
evaluation 184, 183–185
hospital admission 185
ill-appearing child 184, 185–186
intravenous immunoglobulin 185
outpatient management 184
persistent 186
treatment 183–185, 186
well-appearing child 184, 183–185
fibrates 298–299
fluconazole 697, 710–711
Candidiasis prophylaxis 167
drug interactions 368
prophylactic 165
fluorouracil 259
folic acid 535
foliculitis, infectious 710
food availability 293
aversion 291
drug interactions 361
refusal 281
see also nutrition
foreign body aspiration 568
wheeze 573
fosarnet 816
cytomegalovirus 728
drug interactions 368
herpes simplex virus 732
varicella zoster virus 735
foster care 799
fungal infections 695–717
CNS 504
diagnosis 696
dimorphic fungi 715–717
 invasive 711–717
mucosal 710–711
opportunistic 711–715
oral mucosa 535–537
orbit 529–530
physical findings 696
pulmonary 571–572
sinusitis 550
skin 476–483, 695–710
 treatment 708
fungin 116
fusion inhibitors 336, 354–355
formulary 812
resistance 405–406
Gag proteins 335–336
Gag/Pol polyprotein precursor 404
ganciclovir 817
cytomegalovirus 726
drug interactions 368
prophylaxis 166
resistance 726
gastritis 291
gastrenteritis 196
bacterial 193, 196
viral 192
gastroesophageal reflux 573
gastrointestinal bleeding 612–614
CMV infection 182
gastrointestinal disease 602–616
cytomegalovirus 182, 723–724, 725
evaluation 604–616
CMV infection 182
HIV-infected children 602–604
malnutrition 603
management 605, 604–616
recognition 605
signs/symptoms 604
gastrointestinal emergencies 192–198
gastrointestinal tract absorbptive capacity 603
brush border enzymes 603
obstruction 197
pathogenesis 612
 gender inequality 261–262
genital development stages 221
genital infections, herpes simplex virus 259–261, 731
genital warts 253, 257
giardiasis 613–614
gingival erythema, linear 539, 604
gingivitis, necrotizing ulcerative 539
gingivostomatitis, herpes simplex virus 483–484
glial cells 511–512
global access to care/treatment 778
glomerular disease 624–627
evaluation 626
treatment 626–627
glomerulonephritis 622–623
mesangial proliferative 626
glomerulopathy, minimal change 626
glomerulosclerosis, focal segmental 625
glucose administration 195
metabolism abnormalities 385–386, 634
diagnosis 388
glucose-6-phosphate dehydrogenase deficiency 590
glutathione 276
gp41 envelope glycoprotein 336
gp160 30
grandparents 791–794
granulocyte-colony stimulating factor (G-CSF) 14
grief 781–784
adult 788–791
books 792
children who lose a parent 773, 784–785
developmental considerations 783
grandparents 791–794
parents dying before children 791
reading materials 792
resources 786, 787
sibling loss 785
grieving process 781
assisting children 785–788
growth 273–277
antiretroviral therapy 276
assessment 149
catch-up 286, 287
HAART 276
impairment 275–300
reference data 274–291
velocity 274–287
growth factors 14
growth failure 273–279, 630–631
diagnosis 631
mechanisms 630
non-hormonal causes 631
treatment 631
growth hormone (GH) deficiency 296–297, 630
lipodystrophy syndrome treatment 298
supplementation 297
treatment 831
 guardianship 798–799
gynecology, adolescents
care 227
non-infectious 228–244
sexually transmitted infections 244
Haemophilus influenzae type b 663
meningitis 668
pneumonia 665, 666
vaccination 571
head circumference 278
health education
adolescents 262
sexually transmitted infections 244–245
Health Maintenance Organizations (HMOs) 774
heart failure, congestive 555
heat denaturation of plasma (HD-Ag) testing 182
height
growth velocity 276
measurement 278
Helicobacter pylori 611–612
helper T-cells see CD4+ T-cells
hematemesis 613
hematologic problems 588–598
hematoma 622, 621–622
hemolytic–uremic syndrome/thrombotic thrombocytopenic purpura 626
hepatitis c 590
hepatitis c cofactor B deficiency 596–597
hepatic abscess 198
heptatic failure, antiretroviral therapy discontinuation 433
hepatitis
cholestatic 615
CMV 724
hepatitis B virus 615
prophylaxis 169
seroprevalence 56
transmission 169
hepatitis C virus 615
prophylaxis 169
transmission 169
hepatomegaly 614–615
herpes simplex virus (HSV) 730–732
chronic 484, 484–485
clinical manifestations 730–731
clinical syndromes 726
diagnosis 260, 483, 731–732
disseminated disease 731
epidemiology 730
esophagitis 196, 198, 611, 730–731
genital infections 259–261, 731
erythematous rash 483–484
lesions 259
odynophagia 610
oral infection 537, 604, 730
orolabial 730
prophylaxis 168
reactivation 730
skin infection 483–485
suppressive therapy 261
treatment 260, 260–261, 727, 732
herpes zoster 485, 733–734
herpesvirus infections 721–737
clinical syndromes 726
highly active antiretroviral therapy
(HAART)
adherence 206–207, 212
CD4+ T-cell levels 40–41, 42, 42–43, 156
CD8+ T-cell levels 42
changes to reverse fat redistribution syndrome 388–389
cNS disease 513
cytomegalovirus 729
directly observed therapy 214
ey early treatment 90
focal segmental glomerulosclerosis 625
growth 276
failure 631
HIV natural history 55
immune restoration 40–43
initiation 287
guidelines 416–417
lymphocyte population changes 42
mega-HAART 435
metabolic complications 382
MTCT rate 109
neoplastic disease 638
neurobehavioral function 323
neuroprophylaxis 513–514
opportunist infection prophylaxis discontinuing 156, 162, 163
hirsutism management 233
histoplasmosis diagnosis 715
prophylaxis 165
treatment 708, 715–716
HIV accessory proteins 31
biology and antiretroviral therapy 335–336
classification 17
co-receptors 20–22
drug-resistant strains 262
gene expression 26
genomic organization 24, 404
host cell entry 20–22
integration 25
late viral protein post-translational modification 30
life cycle 20–31
nuclear localization/entry 25
origin 17
phenotyping assays 498
plasma concentrations 48–50
pre-integration complex 25
quantitative assays 47
replication cycle 23
Rev post-transcriptional regulation of gene expression 27–30
reverse transcription 22–25
RNA 29
packaging 31
plasma concentration 56–57, 153
quantitation 46–47
structural message translation 30
transcription regulation 27
viral envelope glycoprotein glycosylation 30
viral gene expression control 25–27
virus 19, 761
assembly 30–31
building 31
maturation 31
structure 17–20
virology 17–32
HIV disease clinical virology 44–47
immunology 42–43
progression monitoring 150–155
HIV infection
adults natural history 47–48
progression 48–51
care of child 148
changes following infection 48
chronic illness 33–34, 296–214
classification of pediatric 51, 54
diagnosis 162–164
HAART impact on natural history 55
horizontally-acquired 55–56
host factors 50
immune abnormalities 34–37
immunologic classification 148
latent 47
long-term non-progression 34
monitoring 46–47
natural history 47–58
HAART 55
non-progression 34
prevention in adolescents 223–226
primary 32–33
adult 47
progression
adults 48–51
children 56–58
clinical factors 57–58
host factors 50
viral factors 50–51
progressive 33–34
reporting 78–87
transient 58
vertical 51–54
viral factors 50–51
see also epidemiology
HIV testing
acceptance rates 86–87
prenatal
developing countries 91–92
US 86–87
resource-poor settings 119
US 86–87, 118–119
voluntary 118–119
Index
metabolism 273–277
metformin 298
metronidazole, trichomoniasis treatment 250
microangiopathy, HIV 526, 527
microbicides, contraception 238
micronutrient deficiency 279–285, 291
therapeutic disease 292
micronutrient status 301
Microsporidia 167
Microsporum 710
mid-arm circumference (MAC) 278, 280
middle ear effusion 549
mitochondrial toxicity 299
cofactor therapy 300
delayed manifestations 391–392
NRTIs 299, 300, 389–390, 391–392
prevalence 391
treatment 300
molluscum contagiosum virus 491
preparation 492
skin disease 486–493, 522
molluscum contagiosum virus
eyelids
mothers, breastfeeding impact 115
mother-to-child transmission (MATCH) 80–85
antiretroviral
pregnant women 121
safety 125
breastfeeding avoidance 119–120
cesarean delivery 87, 135–162
before labor and ruptured membranes 120–121
interventions 107–117
prevention 107–126, 778
developing countries 91–92
perinatal cascade 85–47
postexposure prophylaxis model 454
strategies 118, 118–126
rates 107–126
resistance HIV 125–126
-resource poor settings 118
-prevention 91–92
-amount of virus exposure 108–115
-risk reduction 135–162
trends 84–85
virus exposure
amount 108–115
-duration 115
-intrapartum 115–116
-postnatal 116
motor dysfunction, referral 317
motor functioning 316
motor skill evaluation 312–316
mucosa-associated lymphoid tissue (MALT) 6–17
lymphoproliferative lesions 645
mucosal defenses 13
mucosal immunity 6–17
mucous membrane transmissions 453
multisystem disease 392
mycobacterial infection
non-tuberculous 692
pulmonary 571
Mycobacterium avium complex (MAC) 571
acquisition 686
bacteremia 687
blood cultures 687
clinical presentation 687–688
diagnosis 687–688
disseminated infection 685–692
drug interactions 691–692
epidemiology 685
fever 183
microbiology 686–687
pathogenesis 686–687
prevention 686, 690
prophylaxis
-discontinuing on HAART 156
strongly recommended 162–163
treatment 690, 688–692
Mycobacterium avium intracellulare 616
Mycobacterium tuberculosis 674
bacterial replication 675
see also tuberculosis
myelitis, varicella zoster virus 734
myelopaties 515
myocariditis 555, 563
myoperiheral saladenitis (MESA) 645
myopathies 516
myringotomy with tube placement 551
nails
dermatophytosis 477–478
onychomycosis 481, 710
natural killer (NK) cells 6–14, 43
function defects 36
nausea 611–612
needle stick injury 459
transmission 762
Nef 32
neglect, medical 801
Neisseria gonorrhoeae cervicitis 250–251
pelvic inflammatory disease 251–254
nelfinavir (NFV) 350–351, 811
adverse effects 351
antiviral effects 351
drug interactions 368
pharmacokinetics 351
postexposure prophylaxis 461
resistance 351
neoplastic disease 637–646
CNS 504
diagnosis 638
epidemiology 637–638
management 638
non-AIDS-defining 638
nephritis 624–625
interstitial 622–623
nephropathy, HIV-associated 625
nephrotic syndrome 624–625
neurobehavioral assessment 316–317
developmental change over time 317–319
differential diagnosis 320–323
domains 317
functions 313
longitudinal 317–323
motor-skill evaluation 312–316
neuroimaging 321
practice effects 319
referral 317
repeat testing frequency 319
test administration procedures 319–320
neurobehavioral function
abnormalities 310
antiretroviral therapy 323
HAART 323
neurodevelopment
function in vertical transmission 310
serial assessment 329
neurologic dysfunction 503–508, 516
emergency department presentation 182
feeding difficulties 293
neurobehavioral assessment 321–322
neurologic emergencies 198–202
neurological assessment 149
neuro-ophthalmology 531
neuropsychologic impairment 312–316
neuropsychological impairment 312–316
neurophil 671
neurotropic factors, host-derived 511–512
neuropenia 183–184, 591–593
causes 592, 591–592
diagnosis 592–593
drug-induced 592
neutrophils 6–14, 37
neutropenia 591
nevirapine (NVP) 345–346, 365, 809
adverse effects 346
antiviral effects 345
drug interactions 368
pharmacokinetics 345–346
prophylaxis 110
postexposure 462
resistance 345
zidovudine combination 109
nitazoxanide 613–614
non-Hodgkin's lymphoma 638, 641–644
classification 641
oral 538
prognosis 641
staging 641
treatment 643–644
non-nucleoside reverse transcriptase inhibitors (NNRTIs) 22–25, 335, 345–347
CNS disease 513
combination therapy 356
distribution 362
drug interactions 691–692
formulary 809–810
initial therapy 428–429
salvage therapy 356
therapeutic drug monitoring 440
tuberculosis treatment 679–681
see also named drugs
nucleic acid sequence-based amplification (NASBA(r)) 46
nucleoside reverse transcriptase inhibitors (NRTIs) 22–25, 335, 336–344
CNS disease 512–513
combinations 336–337, 355–356, 366
dual backbone 424–426
distribution 362
dual therapy 428
dyslipidemia 106
fat redistribution syndrome 386
formulary 807–809
initial therapy 428–429
neutropenia 591
neutrophils 6–14, 37
neutropenia 591
nevirapine (NVP) 345–346, 365, 809
adverse effects 346
antiviral effects 345
drug interactions 368
pharmacokinetics 345–346
prophylaxis 110
postexposure 462
resistance 345
zidovudine combination 109
nitazoxanide 613–614
non-Hodgkin's lymphoma 638, 641–644
classification 641
oral 538
prognosis 641
staging 641
treatment 643–644
non-nucleoside reverse transcriptase inhibitors (NNRTIs) 22–25, 335, 345–347
CNS disease 513
combination therapy 356
distribution 362
drug interactions 691–692
formulary 809–810
initial therapy 428–429
salvage therapy 356
therapeutic drug monitoring 440
tuberculosis treatment 679–681
see also named drugs
nucleic acid sequence-based amplification (NASBA(r)) 46
nucleoside reverse transcriptase inhibitors (NRTIs) 22–25, 335, 336–344
CNS disease 512–513
combinations 336–337, 355–356, 366
dual backbone 424–426
distribution 362
dual therapy 428
dyslipidemia 106
fat redistribution syndrome 386
formulary 807–809
initial therapy 428–429
interactions 366
mitochondrial toxicity 299, 380, 389–390
delayed manifestations 391–392
neutrophil-associated mutations 400–402
NRTIs (cont.)
pharmacokinetics 337
resistance 400–403
excision mechanisms 400–402
positional effects 402
steric effects 402
salvage therapy 356
therapeutic drug monitoring 440
see also named drugs
nucleoside-associated mutations (NAMS) 400–402
nucleotide reverse transcriptase inhibitors
formulary 810
resistance 400–403
nursing intervention in adherence 213–214
nutrients
increased losses 294–296
intake 279
requirement increase 296
nutrition 273–277
deficiencies 273–274
anemia 589–590
see also food; malnutrition
nutritional assessment 277, 278
laboratory studies 279–285
routine 277–287
nutritional status, body composition 276
nutritional support 277
enteral feeding 293, 295
malabsorption 295
parenteral feeding 296
tube feeding 294
nystatin 697, 695–707, 710–711
odynophagia 610–611
oligomennorrea 231–233
oral hygiene, online resources 826–834
onchomycosis 481, 710
ophthalmic problems 521, 520–532
clinical examination 520–522
CMV retinitis 723
drug ocular toxicity 531–532
epidemiology 520
external disease 522–526
neoplasms 530
neuro-ophthalmic signs 531
orbit 529–530
posterior segment disease 526–529
screening examination frequency 522
opsonins 6
oral hairy leukoplakia 537–538
oral health 535–541
periodontal tissues 539–541
preventive measures 541
salivary glands 538–539
oral intake, decreased 290–294
oral lesions 336
CMV 723–724
neoplasms 538
prevention 541
relief 291–293
oral mucosa
infectious diseases 476–498
lesions 535–538
non-infectious diseases 498–501
orbit, infections 529–530
organ system disease assessment 153–155
orphans 773
oseltamivir 817
osteomyelitis 670
osteonecrosis 299
osteopenia 299
osteoporosis 299
acute
antimicrobial therapy 547
clinical presentation 544
diagnosis 545
epidemiology 543–544
microbiology 546–547
natural history 544
pathogenesis 544
chronic 546–547
suppurative 549
microbiology 546–547
prevention 550–551
treatment 547–550
outreach to ‘at risk’ youth 262
ovarian tumors 252
oxandrolone 631
p24 antigen detection 45, 101–102
parenteral nutrition 296
parents
adherence 206–207
adoption of infected child 768
bereavement 788–791
biological 797
death 773, 784–785, 790
diagnosis disclosure 782
food availability 293
grief 788–791
dying before children 791
guardianship plans 798–799
oral lesions 336
CMV 723–724
neoplasms 538
prevention 541
relief 291–293
oral mucosa
infectious diseases 476–498
lesions 535–538
non-infectious diseases 498–501
orbit, infections 529–530
organ system disease assessment 153–155
orphans 773
oseltamivir 817
osteomyelitis 670
osteonecrosis 299
osteopenia 299
osteoporosis 299
acute
antimicrobial therapy 547
clinical presentation 544
diagnosis 545
epidemiology 543–544
microbiology 546–547
natural history 544
pathogenesis 544
chronic 546–547
suppurative 549
microbiology 546–547
prevention 550–551
treatment 547–550
outreach to ‘at risk’ youth 262
ovarian tumors 252
oxandrolone 631
p24 antigen detection 45, 101–102
parenteral nutrition 296
parents
adherence 206–207
adoption of infected child 768
bereavement 788–791
biological 797
death 773, 784–785, 790
diagnosis disclosure 782
food availability 293
grief 788–791
dying before children 791
guardianship plans 798–799
illness 293
non-custodial 797
permanent planning 773
refusal to seek treatment 801
responsibilities 797
rights 797
parotitis 538–539
Pediatric AIDS Clinical Trial Group: (PACTG)
Pediatric Adherence Questionnaire
Modules 208–210
Pill Count Form 210
peer educators, adolescents 262
pelvic inflammatory disease 251–255
diagnostic criteria 254–255
etiology 254
treatment 255
regimens 256
penicilliosis 698, 716
treatment 708
*Penicillium marneffei* 483, 716
pentamidine isothionate 818
aerosolized 576
drug interactions 368
PCP treatment 748
pericardial effusions 563–564
drug interactions 589
pericarditis 556
perinatal prevention cascade 85–87
perinatal transmission, antiretroviral prophylaxis 138–168
pericardiocentesis 559
pericarditis 556
periodontal tissues 539–541
periodontitis, necrotizing ulcerative 539–540
peripheral blood mononuclear cells (PBMCs) culture methods 102
peripheral nervous system (PNS), malnutrition 275–299
peripheral neuropathy 515
perirectal abscess 669
peritoneal signs 197
periventricular white matter, bright signal 510
permanent custody planning 786–799
adoption 799
benefit entitlement for child 787–798
foster care 799
guardianship 798–799
obstacles 796
power of attorney 798
phagocytes 13
cell function defects 37
pharmacy refill records 211
phenytoin seizures 201
physical and occupational therapist 317
pill counts, adherence 210–211
Pills Identification test (PIT) 210
pill-swallowing training 213
placental membrane inflammation 116
platelets, survival 593
play, infected child 765
pneumococcal infections, invasive (IP)
183
pneumococcal vaccine, heptavalent conjugate (PCV7) 551
*Pneumocystis jiroveci* pneumonia (PCP) 567
CMV co-infection 189
ear infections 549
fever 183
incidence 88
presentation 178–192
prophylaxis 156
aerosolized pentamidine 576
discontinuing on HAART 156
infants 148
strongly recommended 157–162
TMP-SMX 157–162, 163, 164
respiratory distress 187, 189
therapy 748
pneumonia
abdominal pain 196
bacterial 672, 665–667
CMV 724, 725
diagnostic evaluation 572
differential diagnosis 665–666
fungal 571–572
infectious 571–572
measles 493
mycobacterial 571
viral 571–572
see also *Pneumocystis jiroveci* pneumonia (PCP)
pneumothorax, spontaneous 577
podophyllin 257
Pol proteins 335–336
polycystic ovarian syndrome 231, 232
management 233
polymerase chain reaction (PCR)
diagnosis of infants born to HIV-infected women 135–169
HIV DNA 45
reverse transcription 46
polymorphonuclear leukocytes (PMNs), defects 37
postexposure prophylaxis 181, 450–464
adolescents 460
adults 460
adverse effects of drugs 461
animal models 453–454
antiretroviral therapy 460–462
bite wounds 459–460
characteristics of exposed patient 457
drug toxicity testing 463
exposure risk category 457
postexposure prophylaxis (cont.)
failure potential 454
follow-up 462
implementation 462
MTCT prevention model 454
needle sharing 460
non-occupational exposure 454–456
percutaneous exposures 459–460
puncture wounds 459
reporting 463
sexual exposure 456–459
significant exposure 463
transmission prevention 453
postexposure testing 181
potassium 618–619
poverty 773–774, 778
povidone iodine 710
power of attorney 798
pravastatin 298–299
precautions
infections 764–768
outside hospital environment 764–768
standard 763, 762–763, 769
pregnancy
adolescents 243
amenorrhea 230
antiretroviral therapy 121
combination 121
pre-integration complex (PIC) 25
prenatal care 85–86
prenatal testing 86–87
primaquine 818
primary healthcare provider (PCP) 774–775
probenecid, drug interactions 368
pregesternol 335–336
combination 121
pre-exposure prophylaxis
antiretroviral against perinatal transmission 135–162
see also postexposure prophylaxis prostaglandin E 1.300
protease 404, 405
protease inhibitors (PIs) 31, 335–336, 347–354
CNS disease 513
combination therapy 356
CYP 362
distribution 362
drug interactions 368, 691–692
dyslipidemia 385
fat redistribution syndrome 632
formulary 810–812
fusion 336
insulin resistance 385
lipid metabolism 386
resistance 348, 404–405
therapeutic drug monitoring 440
tuberculosis treatment 679–681
transmission 762–763
protein
malabsorption 295–296
recommended daily intake 286, 287
resistance 348, 349
requirement estimation 286
visceral status 279
protein C deficiency 504, 596–597
protein S deficiency 504, 596–597
protein–calorie malnutrition 273–279
protein/creatinine ratio 623–624
provider assessment of adherence 210
Pseudomonas aeruginosa
bacilhermia 664–665
catheter-associated 665
pneumonia 572, 667
Pseudomonas aeruginosa pneumonia 572
skin lesions 669
psychiatric disturbances 508
psychological assessment 316–317
psychometric tests 313, 321
psychosocial issues 772–773
bereavement 781–794
distinctive for HIV 773
grief 781–794
referral 789
puberty, delayed 228, 631
differential diagnosis 229
malnutrition 275
pulmonary disease 567–585
CMV 724
diagnostic evaluation 584
evaluation 577–585
infection prophylaxis 374
malignant 580
management 582, 577–585
respiratory problems 568–577
tuberculosis 676
pulmonary function tests 581
pulmonary hypertension 556
pulmonary lymphoid hyperplasia 567, 568
management 570
pulse oximetry, fever 186
pyelonephritis 668
pyrazinamide 678, 679, 818
pyuria 623, 622–623
racial factors
incidence of infection 78–92
infected women 83
pregnancy care 85
radiology studies, emergency department
179–198
referral
acne, 620
adolescents 223
cardiovascular disease patients 565
psychosocial issues 789
renal disease 618–627
renal failure, acute 620, 619–620
causes 619–620
reproductive health 669
non-infectious 228–244
sexually transmitted infections 244
resistance
abacavir 342
amprenavir 348
antibiotics 661
bacterial infections 661
Campylobacter 662
Escherichia coli 668
Haemophilus influenzae type b 663
non-typhoidal Salmonella 662
pneumonia 666
Pseudomonas 662
Staphylococcus aureus 663
Staphylococcus epidermidis 663
Streptococcus pneumoniae 186, 661–662
tuberculosis 680–681
antiretroviral therapy 125–126, 336, 397–411
assays 406–407
genotyping 406–407
phenotyping 407
use in clinical management 409
azidothymidine 345
delavirdine 346
didanosine 338
efavirenz 347
emtricitabine 344
enfuvirtide 354–355
fusion inhibitors 405–406
HIV strains 282
indinavir 349
lamivudine 341
lopinavir plus ritonavir 350
mechanisms 397
nevirapine 351
nevirapine 345
NNRTIs 208, 403–404
NRTIs 400–403
excision mechanisms 400–402
position effects 402
steric effects 402
nucleotide reverse transcriptase inhibitors 400–403
protease inhibitors 348, 404–405
reverse transcriptase 400
ritonavir 351–352
saquinavir 353
 stavudine 339–340
tenofovir 343
testing in clinical practice 410–411
zalcitabine 341
zidovudine 337
resource-poor settings
breastfeeding avoidance 119
 counseling 119
HIV testing 119
malnutrition 300–301
mortality 91
MTCT 118
prevention 91–92
WHO Interim Guidelines 419
respiratory distress
causes 187, 187–188
emergency department presentation 187–192
evaluation 188, 188–189
investigations 188
lobar infiltrates 191
segmental infiltrates 191
treatment 190, 190
respiratory problems 568–577
respiratory rate 581–585
respiratory syncytial virus
f ander 183
presentation 188–189
respiratory syncytial virus
f ander 183
presentation 188–189
retinal ischemia 526
retinal necrosis, progressive outer 529, 528–529
retroviral syndrome, acute 47
Rev 29
post-transcriptional regulation of HIV
 gene expression 27–30
reverse transcriptase 402
resistance 400

© Cambridge University Press
www.cambridge.org
reverse transcriptase inhibitors
see non-nucleoside reverse transcriptase inhibitors (NNRTIs); nucleoside reverse transcriptase inhibitors (NRTIs); nucleotide reverse transcriptase inhibitors
reverse transcription 22–25, 493
reverse transcription-polymerase chain reaction (RT-PCR) 46
riboflavin 300
rifabutin 678, 689, 690, 691
rifampin 365, 678, 679–680
rifabutin 678, 689, 690, 818
ritonavir (RTV) 351–352, 810, 811
salmonella meningitis 668
Saquinavir (SQV) 352–353, 812
selenium deficiency 276
selenium deficiency 44
serendipity 44
serendipity 44
seroprevalence in adolescents 220–226
sexual identity 222
sexual intercourse, latex condoms 168–169
sexual maturation 220–221
sexual transmission 80
shingles 785, 790
Single Use Diagnostic System (SUDS) 100
sinus aspiration 546, 549
sodium 618–619
soft tissue infections, bacterial 668–669
Somatotropin, drug interactions 368
speech deficits 312–315
speech deficits 312–315
speech, survival 224
sex steroid deficiency 631
sexual abstinence 238
sexual abuse 261–262
sexual experimentation 221–222
sexual exposure
postexposure prophylaxis 456–459
unprotected 452
sexual history, adolescents 227
sexually transmitted infections
adolescents 227, 244
health education 244–245
HIV impact 262
screening 244–245
secondary prevention 261–262
SHADISS assessment 224, 226
sharps, contaminated 763
sibling loss 785, 790
Single Use Diagnostic System (SUDS) 100
sinus aspiration 546, 549
sodium 618–619
soft tissue infections, bacterial 668–669
Somatotropin, drug interactions 368
speech deficits 312–315
relation 46
spermicides
contraindication in cervicitis 251
vaginal 239
spleen 6–30
splenectomy 595–596
splectomy 197, 198
sports, infected child 765
squamous intra-epithelial lesions 255
Stages of Change Model 207
adherence 214
standard precautions 762–763, 769
Staphylococcus aureus 663
bacteremia 665
catheter-associated 666
central venous catheter infections 669
impetigo 493
pneumonia 665
Staphylococcus epidermidis 663
catheter-associated bacteremia 665
central venous catheter infections 669
stevorosis 290
status epilepticus 201
stavudine 336–337, 339–340
adverse effects 340
antiviral effects 339–340
drug interactions 368
neurobehavioral deficits 323
pancreatitis 196
pharmacokinetics 340
postexposure prophylaxis 461
resistance 339–340
starvation 290
steatorrhea 295
steatosis 614–615
Stevens–Johnson syndrome 501
antiretroviral therapy discontinuance 433
nevirapine 346
nevirapinase 291
Streptococcus pneumoniae 661–662
antibiotic resistance 186
bacteremia 664
impetigo 493
meningitis 667–668
treatment 667–668
pneumonia 665, 666
streptomycin 678, 687
stress, family 774
stroke 504
summer camp 768
Supplemental Security Income 775–776, 799–800
appeal process 800
information needed to apply 800
support, family 170–171
infected child 170
surfaces, contaminated 763
survival, height growth velocity 276
swallowing difficulties 610–611
syndrome of inappropriate antidiuretic hormone (SIADH) 618–619
syphilis
congenital 670–671
treatment 671
T-cell receptors (TCR) 7
T-cells 7, 12
help for antibody production 15
memory 14–15
numbers 15
phenotype 14–15
rhymic 14
Tamm–Horsfall protein 623
Tanner sexual maturation scale 220–221
TAR 28
Tet 28
HIV transcription regulation 27
tests 540–541
tenofovir (TDF) 343–344, 810
adverse effects 344
antiviral effects 343
drug interactions 368
NRTI combination 336–337
pharmacokinetics 343–344
resistance 343
terfialine 697, 710
testing for HIV
adolescents 222–223
emergency department 180–202
postexposure 181
testosterone replacement 631
TNF-α cells 9–10
TNF-β cells 9–10
thalidomide, drug interactions 368
therapeutic drug monitoring 439–446
children’s issues 440–441
clinical situations 446
clinical trials 441–442
commercial laboratories 445
concentration ratio 443–444
dosage alteration 446
drug candidates 439–440
intra-patient variability 444
IQ ratio 442
limitations 444
logistical issues 444–445
pharmacokinetic modeling 444
plasma concentrations 439
plasma levels 439, 442
plasma sampling 443–444
practical issues 445–446
target concentrations 443–444
therapeutic range 440
toxicity 442
trough concentrations 443, 443
therapeutic window 439
thiamine 300
thrombocytopenia 593–596
causes 593, 594
diagnostic evaluation 594
laboratory evaluation 594–595
management 595
mild 593–594
treatment 595–596
thrombophilia 299
thymidine analog mutations (TAMS) 400–402
thymus development 14
lymphoproliferative cysts 577
thyroid abnormalities 296–297
function derangement 632
thyroid-stimulating hormone (TSH) 632
thyrotrophin-releasing hormone (TRH) 632
thyroxine (T4) 632
tinea capitis/corpus/fascialis 480, 710
tinea versicolor 710
tipranavir 365
TMP-SMX 819
bacterial infection prophylaxis 164
drug eruption 499
drug interactions 368
Escherichia coli resistance 668
PCP prophylaxis 157–162, 163, 164
therapy 182, 748
toxoplasmosis prophylaxis 163
Toll-like receptors 7
toxic epidermal necrolysis 501
Toxoplasma CNS infection 504
ocular infection 528, 526–528
toxoplasmosis fever 183
prophylaxis 163–164
transmission 759–760
adolescents 219–231
avoidance of risks 763
body fluids 760–761
day-care centers 768
heterosexual 83, 219–237, 244
household risks 761, 762
infection in home 764
injection drug use 83
male-to-male sexual 220–238
modes 759
needle-stick injury 459, 762
outside hospital environment 764, 764–768
prevent 135–162
precautions 762–763
prevention 453
prophylaxis 121
antiretroviral 135–162
postexposure 453
risk 453, 769
after potential exposure 450–453
and from children 768–762
contact type 452
infected blood 452
source material type 455
vertical and neurodevelopmental function 110
see also mother-to-child transmission
treatment child involvement in decisions 170
in plan 155
counsel for minors 801
directly observed therapy (DOT) 214
family involvement in decisions 170
global access 778
infected child 155
life-threatening complications 181
respiratory distress 190
see also adherence
Treatment Regimens Enhancing Adherence in Teens (TREAT) Program 214
Treponema pallidum 670–671
triazoles 711
triceps skinfold thickness 278
trichloroacetic acid 257
trichomegaly 500
trichomoniasis 245, 249–250
diagnosis 249–250
treatment 250
Trichophyton 710
Trichophyton rubrum 477–478
trimethoprim–sulfamethoxazole see TMP-SMX
trimetrexate 820
drug interactions 368
trimetrexate/leucovorin 748
tube feeding 294
tuberculin skin test 676–677
tuberculosis 674–682
active disease 675
antibiotic resistant 680–681
bacille Calmette-Guérin vaccine 681–682
clinical presentation 676
diagnosis 676–677
directly observed therapy (DOT) 679, 681
disease 678–680
epidemiology 674
extrapulmonary disease 676
immunity 675
latent 677–679

<table>
<thead>
<tr>
<th>Western blot assay 99–100</th>
</tr>
</thead>
<tbody>
<tr>
<td>wheeze 573</td>
</tr>
<tr>
<td>therapy 576</td>
</tr>
<tr>
<td>World Health Organization (WHO): Expanded Program on Immunization 682</td>
</tr>
<tr>
<td>Interim Guidelines for Resource-Limited Settings 419, 421</td>
</tr>
<tr>
<td>wounds</td>
</tr>
<tr>
<td>bites 459–460</td>
</tr>
<tr>
<td>puncture 459</td>
</tr>
<tr>
<td>zalcitabine 341–342, 807</td>
</tr>
<tr>
<td>adverse effects 342</td>
</tr>
<tr>
<td>antiviral effects 341</td>
</tr>
<tr>
<td>drug interactions 368</td>
</tr>
<tr>
<td>NRTI combination 336–337</td>
</tr>
<tr>
<td>oral injury 611</td>
</tr>
<tr>
<td>pancreatitis 196</td>
</tr>
<tr>
<td>pharmacokinetics 342</td>
</tr>
<tr>
<td>resistance 341</td>
</tr>
<tr>
<td>zidovudine 336–338, 807</td>
</tr>
<tr>
<td>adverse effects 338</td>
</tr>
<tr>
<td>antiviral activity 337</td>
</tr>
<tr>
<td>drug interactions 368</td>
</tr>
<tr>
<td>drug-induced reduced clearance 365</td>
</tr>
<tr>
<td>HIV encephalopathy risk reduction 310</td>
</tr>
<tr>
<td>MTCT prophylaxis 84</td>
</tr>
<tr>
<td>rate 109</td>
</tr>
<tr>
<td>risk reduction 135–162</td>
</tr>
<tr>
<td>neurobehavioral deficits 323</td>
</tr>
<tr>
<td>nevirapine combination 109</td>
</tr>
<tr>
<td>oral injury 611</td>
</tr>
<tr>
<td>perinatal 84</td>
</tr>
<tr>
<td>pharmacokinetics 337</td>
</tr>
<tr>
<td>postexposure prophylaxis 481</td>
</tr>
<tr>
<td>prophylactic 110, 121, 138–168</td>
</tr>
<tr>
<td>received by mothers and infants 87</td>
</tr>
<tr>
<td>resistance 337</td>
</tr>
<tr>
<td>z-scores 274–287</td>
</tr>
</tbody>
</table>